The latest issue of Bio Business magazine includes an article about the global obesity epidemic that highlights the efforts of Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to tackle the problem by focusing on the development of Omega-3 therapies and diagnostics.
“The consequences of an Omega-3 deficiency could be obesity, diabetes, elevated triglycerides, high cholesterol and coronary heart disease,” says Rachelle MacSweeney, president and COO, of Pivotal.
The company sells a 90% pure Omega-3 product that is formulated with a unique ration of Eicosapentaenoic acid (EPA) and Docosahexaenoic (DHA). EPA and DHA are types of Omega-3 fatty acids. EPA is a strong anti-inflammatory agent while DHA offers positive effects on the cardiovascular system.
“It’s a six-to-one ratio of EPA to DHA, whereas a lot of the over-the-counter products are about one-to-one,” Ms. MacSweeney is quoted as saying in the article. “Our product has a lot of anti-inflammatory properties and obesity, diabetes, cardiometabolic diseases are all inflammatory-based.”
A copy of the article can be accessed here.